Nuclear expression of lysyl oxidase enzyme is an independent prognostic factor in rectal cancer patients by Liu, Na et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Nuclear expression of lysyl oxidase enzyme is an independent prognostic factor in
rectal cancer patients
Liu, Na; Cox, Thomas R; Cui, Weiyingqi; Adell, Gunnar; Holmlund, Birgitta; Ping, Jie; Jarlsfelt,
Ingvar; Erler, Janine T; Sun, Xiao-Feng
Published in:
OncoTarget
DOI:
10.18632/oncotarget.9623
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Liu, N., Cox, T. R., Cui, W., Adell, G., Holmlund, B., Ping, J., ... Sun, X-F. (2017). Nuclear expression of lysyl
oxidase enzyme is an independent prognostic factor in rectal cancer patients. OncoTarget, 8(36), 60015-60024.
https://doi.org/10.18632/oncotarget.9623
Download date: 03. Feb. 2020
Oncotarget60015www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 36), pp: 60015-60024
Nuclear expression of lysyl oxidase enzyme is an independent 
prognostic factor in rectal cancer patients
Na Liu1,2, Thomas R. Cox3, Weiyingqi Cui1, Gunnar Adell1, Birgitta Holmlund1, 
Jie Ping4, Ingvar Jarlsfelt5, Janine T. Erler3 and Xiao-Feng Sun1
1Department of Oncology and Department of Clinical and Experimental Medicine, Linköping University, SE-58185, Linköping, 
Sweden
2State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical 
University, 710032, Xi’an, China
3Biotech Research and Innovation Centre (BRIC), University of Copenhagen, DK-2200, Copenhagen, Denmark
4Shanghai Center for Bioinformation Technology, 201203, Shanghai, China
5Department of Pathology, Ryhov Hospital, SE-55111, Jönköping, Sweden
Correspondence to: Xiao-Feng Sun, email: xiao-feng.sun@liu.se
Keywords: lysyl oxidase, nuclear localisation, prognosis, rectal cancer patient
Received: February 20, 2016    Accepted: May 12, 2016    Published: May 26, 2016
Copyright:  Liu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
Emerging evidence has implicated a pivotal role for lysyl oxidase (LOX) in 
cancer progression and metastasis. Whilst the majority of work has focused on the 
extracellular matrix cross-linking role of LOX, the exact function of intracellular 
LOX localisation remains unclear. In this study, we analysed the LOX expression 
patterns in the nuclei of rectal cancer patient samples and determined the clinical 
significance of this expression. Nuclear LOX expression was significantly increased 
in patient lymph node metastases compared to their primary tumours. High nuclear 
LOX expression in tumours was correlated with a high rate of distant metastasis and 
increased recurrence. Multivariable analysis showed that high nuclear LOX expression 
was also correlated with poor overall survival and disease free survival. Furthermore, 
we are the first to identify LOX enzyme isoforms (50 kDa and 32 kDa) within the 
nucleus of colon cancer cell lines by confocal microscopy and Western blot. Our 
results show a powerful link between nuclear LOX expression in tumours and patient 
survival, and offer a promising prognostic biomarker for rectal cancer patients.
INTRODUCTION
Colorectal cancer (CRC) is the third most common 
cancer worldwide with approximately 694,000 estimated 
deaths. This makes it the fourth most common cause of 
cancer death [1]. Although the treatment of CRC has been 
improved significantly during the past two decades, the 
5-year survival rate has improved only marginally [2]. 
Local and distant recurrence still occur in one third of 
patients with advanced stage (T3 or T4) resectable rectal 
cancer [3]. Therefore, novel molecular biomarkers for the 
identification of patients at high risk of regional relapse 
and distant metastasis are urgently required to further 
refine patient treatment regimens.
Lysyl oxidase (LOX) is a secreted copper-dependent 
amine oxidase, which catalyses the crosslinking of collagens 
and elastin in the extracellular matrix (ECM) and is essential 
for embryonic development and would healing. It is 
synthesized as a 50-kDa proenzyme, secreted, and processed 
into a 32-kDa mature, active enzyme and an 18-kDa 
propeptide (LOX-PP) [4]. In addition to an ECM remodeling 
role, LOX has also been shown to function intracellularly, 
regulating both cell signalling and gene expression [5, 6]. 
However, the precise role of LOX in cancer 
remains controversial. Initially it was identified as a 
tumour suppressor. Ectopic LOX expression was found 
to inhibit Ras-mediated transformation, and decreased 
LOX expression has been reported in several types of 
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cancers [4, 7, 8]. In contrast, recent publications have 
demonstrated the overexpression of LOX in many types 
of solid cancer, including brain [9], head and neck [10], 
oral and oropharyngeal squamous cell [11], breast [12] 
and ovarian cancer [13]. LOX has been shown to promote 
cancer cell proliferation, metastasis and angiogenesis [14, 
15], supporting a role for LOX as a tumour and metastasis 
promoter. One explanation for the seemingly paradoxical 
role of LOX in cancer is likely the existence of multiple 
forms and differential localisation of LOX. Increasing 
evidence indicates that the tumour suppressor activity 
of LOX lies in the cleaved LOX-PP (18-kDa) which can 
re-enter the nucleus following extracellular cleavage 
from the mature enzyme and repress oncogenes such as 
bcl-2 [4, 16–18]. On the contrary, the secreted LOX 
mature enzyme is typically reported to increase ECM 
stiffness, activate oncogenic signalling pathways and play 
a tumour promoting role [19, 20].
Given the paradoxical role of LOX in cancer and 
the potential link to specific localisation, more detailed 
studies are required to determine the relationship between 
its patterns of expression and clinicopathological features, 
which could be used to improve cancer diagnosis and 
treatment in the future. In this study, we analysed LOX 
expression separately either in the cytoplasm, or in the 
nucleus, in a series of rectal cancer specimens from the 
patients participating in a randomized Swedish rectal 
cancer trial of preoperative radiotherapy (RT) with long-
term follow up data [21, 22]. We also charactersied the 
expression and localisation of LOX in three well-known 
colon cancer cell lines. We are the first to show LOX 
(50-kDa and 32-kDa isoform) expression in the nucleus 
of patient samples and in vitro in cancer cells and, more 
importantly, we identify it as an independent prognostic 
factor in rectal cancer patients.
RESULTS
Cytoplasmic and nuclear expression of LOX in 
normal mucosa, primary tumour and lymph 
node metastases
The expression and localisation of LOX was 
investigated in normal mucosa, primary tumour tissue and 
lymph node metastases by immunohistochemistry (IHC). 
LOX expression was detected both in the cytoplasm and 
in the nucleus of normal epithelial cells and cancer cells 
(Figure 1). Thus, in subsequent analyses, cytoplasmic and 
nuclear immunostaining patterns for LOX were scored 
independently. 
When examining cytoplasmic immunostaining 
patterns of LOX, we observed higher levels of LOX 
expression in primary tumour tissue (79% of 77 (non-
RT), and 83% of 60 (RT)) compared to normal mucosa 
(32% of 62 (non-RT), and 63% of 54 (RT)) for both non-
RT (P < 0.001) and RT (P = 0.014) patients (Figure 2A, 
Supplementary Figure 1A). There was no significant 
difference between cytoplasmic LOX immunostaining 
in primary tumour tissue and lymph node metastases 
in either group (non-RT/RT) (P = 0.400 and P = 0.928, 
respectively). The results show that cytoplasmic LOX is 
associated with diseased tissue. 
In contrast, when analysing nuclear immunostaining 
patterns, the frequency of high LOX expression was 
significantly lower in primary tumour (14% of 77, and 
13% of 60) than in normal mucosa (47% of 62, and 70% 
of 54) in both non-RT and RT groups (P < 0.001 for both). 
However, significantly increased expression of LOX in 
the nucleus was observed in lymph node metastases when 
compared with primary tumour in both non-RT and RT 
groups (P = 0.002 and P = 0.0007, respectively; Figure 2B, 
Supplementary Figure 1B). Our data show that changing 
nuclear LOX expression at the primary tumour may be 
a marker of transition to metastasis. Additional analysis 
demonstrated that there was no correlation between high 
cytoplasmic LOX expression and low nuclear LOX 
expression or between low cytoplasmic expression and 
high nuclear expression (P > 0.05).
Since preoperative RT has been well established as 
a standard treatment in rectal cancer, we further evaluated 
the effect of RT on LOX expression and localisation. RT 
significantly increased the expression of LOX in both the 
cytoplasm (P < 0.001) and nucleus (P = 0.010) in normal 
mucosa whereas no significant difference was found either 
in primary tumours (P = 0.543 for the cytoplasm, and P = 
0.873 for the nucleus) or in lymph node metastases (P = 
0.310 for the cytoplasm, and P = 0.960 for the nucleus) 
(Supplementary Figure 2). These results show that although 
normal epithelial cells respond to RT by increasing LOX 
expression, in cancer cells the already high expression and 
localisation patterns of LOX are unaffected by RT. 
The localisation and expression of LOX protein 
in cancer cell lines
To further confirm the subcellular localisation of 
LOX, we examined LOX expression in SW480, SW620 
and HCT116 cancer cell lines using laser scanning confocal 
microscopy. In line with the results obtained in patient tumour 
tissue above, LOX was detected both in the cytoplasm and in 
the nucleus of all three cell lines (Figure 3A). 
Upon examining the expression of LOX by Western 
blot, we detected a clear and strong band of approximately 
52 kDa, which is consistent with the expected size of LOX 
N-glycosylated proenzyme, as well as a weaker band 
around 32 kDa consistent with the mature enzyme form. 
The both bands were detected in whole cell and nuclear 
extracts of SW480 and SW620 cells (Figure 3B). 
The two bands were weak in cytoplasmic extracts of 
SW480 cells and hardly detected in cytoplasmic extracts 
of SW620 cells. In nuclear extracts, both forms were found 
increased in the metastatic cell line SW620 compared to 
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Figure 1: The expression of LOX protein determined by IHC. LOX expression was detected both in the cytoplasm and in the 
nucleus of normal epithelial cells or cancer cells in (A) normal mucosa, (B) primary tumour, and (C) lymph node metastases. 
Figure 2: The frequency of high cytoplasmic and nuclear expression of LOX protein. (A) The percentage of high cytoplasmic 
LOX expression significantly increased from normal mucosa to primary tumour. (B) The LOX expression in the nucleus was significantly 
decreased in the primary tumour compared with normal mucosa and increased from primary tumour to lymph node metastases.
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the parental non-metastatic cancer cell line SW480. The 
presence of 46kDa non-glycosylated proenzyme form was 
also observed in whole cell and nuclear extracts of SW480 
and SW620 cells. Radiation did not affect LOX protein 
expression (neither localisation nor expression) in the two 
cell lines, consistent with the results obtained in the cancer 
tissues above.
Relationship of LOX protein expression with 
clinicopathological variables
Since RT had no influence on LOX expression 
in primary tumour; we combined non-RT and RT 
groups together for further analysis. High nuclear LOX 
expression was correlated to a higher rate of distant 
metastasis and total recurrence (local and/or distant 
recurrence) compared with lower nuclear LOX expression 
(P = 0.046, and P = 0.048, respectively; Figure 4A 
and 4B, Supplementary Table 1). There was no correlation 
of cytoplasmic LOX expression to gender, age, tumour 
node metastasis (TNM) stage, distant metastasis, total 
recurrence or differentiation (P > 0.05, Supplementary 
Table 1). 
In survival analysis, high nuclear LOX expression 
in stage I to III cancers was correlated to poor overall 
cancer-specific survival (OS) (P = 0.017, Figure 4C) and 
disease free survival (DFS) (P = 0.049, Figure 4C). In 
multivariable analysis, the significance still remained after 
Figure 3: The subcellular localisation of LOX protein in colon cancer cell lines. (A) Immunofluorescence of LOX expression 
determined by confocal microscopy in SW480, SW620 and HCT 116 cells. (B) Western blot analysis of LOX expression in cytoplasmic 
and nuclear fractions from SW480 and SW620 cells.
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Figure 4: The relationship between LOX expression in primary tumour and distance metastasis, total recurrence and 
survival. High nuclear LOX expression was related to high rate of distant metastasis (A) and total recurrence (B) compared with low 
nuclear LOX expression in primary tumour. Patients with high nuclear LOX expression had poor OS (C) and poor DFS (C).
Table 1: Multivariable analysis of nuclear LOX expression associated with survival of rectal cancer 
patients
Variablesa
            OS DFS
HR 95% CI P-value  HR 95% CI P-value
Nuclear 
LOX expression
(High vs. Low)
2.975 1.440–6.148 0.003 2.735 1.376–5.438 0.004
Gender 
(Female vs. Male) 
0.644 0.345–1.204 0.168 0.706 0.409–1.218 0.211
Age 
(≥ 66 vs.< 66)
2.169 1.127–4.175 0.021 1.647 0.951–2.853  0.075
TNM stage 
(III vs. I + II)
8.142 4.035–16.431 < 0.001 7.359 4.089–13.242 < 0.001
Differentiation 
(Poorly vs.
Well + Moderately)
0.807 0.389–1.676 0.566 0.620 0.309–1.247 0.180
RT
(With vs. Without)
0.900 0.489–1.656 0.734 0.812 0.477–1.385 0.445
aSignificance was analysed by Cox regression model
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adjusting for gender, age, TNM stage, differentiation and 
RT (P = 0.003 for OS, and P = 0.004 for DFS, Table 1). 
However, cytoplasmic staining of LOX was not related to 
either DFS or OS (P > 0.05, Figure 4C). 
Relationship of LOX protein expression with 
biological factors
We further analysed the relationship between LOX 
expression and biological factors previously investigated 
within the same patient cohort. There was a significant 
positive correlation between cytoplasmic LOX expression 
with survivin, a negative regulator of apoptosis (P = 0.029, 
Table 2). Nuclear LOX expression in the primary tumour 
was also positively correlated with phospho-NF-κB p65 
(Serine 536) expression (P < 0.001), and showed a weak, 
albeit statistically significant positive correlation with 
Ki-67 expression (P = 0.05). 
DISCUSSION
In this study, we demonstrated the presence 
of nuclear localised LOX expression, in addition to 
cytoplasmic expression, in patient material. We have 
shown that nuclear LOX expression was significantly 
increased in lymph node metastases compared to primary 
tumours, and that this high nuclear expression was 
correlated with distance metastasis. Thus our findings 
suggest that LOX localisation may be an important marker 
of transition to metastasis. Altered LOX localisation was 
further confirmed by confocal microscopy and Western 
blot in cancer cell lines. Furthermore, for the first time, 
we showed by multivariable analysis that nuclear LOX, 
not cytoplasmic LOX, was a robust and independent 
prognostic factor in rectal cancer patients. Nuclear LOX 
also proved to be correlated with other biological factors 
(such as NF-κB) known to be associated with patient 
survival. 
Previously, few reports have shown that LOX 
enzyme expression could be detected in the nucleus of 
normal tissue. Kagan et al. first documented the presence 
and retained catalytic activity of LOX mature enzyme 
within the nuclei of rat vascular smooth muscle cells and 
NIH 3T3 fibroblasts [23]. Later, it was demonstrated that 
exogenous mature LOX enzyme could enter the cells and 
concentrate within the nuclei [24]. Here for the first time, 
our results demonstrated the existence of LOX proenzyme 
(50kDa) and mature enzyme (32kDa) within the nuclei 
of colon cancer cells. The precise role of nuclear LOX 
has yet to be determined. Some experimental data have 
shown that LOX catalyses the oxidation of residues in 
histones H1 and H2, which are known to control global 
chromatin compaction and the expression of selected 
genes [6, 14, 25]. 
Both LOX down- and up-regulation has been 
described in CRC as well as other cancers, initially, 
decreased LOX mRNA expression levels were reported 
in CRC patients with non-metastatic disease [26]. 
However, work from both us and other groups observed 
an association of LOX overexpression and CRC 
progression [15, 20, 27, 28]. One important issue is, in 
these studies, that the authors did not profile the nuclear 
localisation of LOX protein. In the present study, our 
data showed the increased expression of LOX in the 
nucleus of the matched patient lymph node metastases 
compared to primary tumour. Furthermore, high nuclear 
LOX expression in primary tumours was also shown to be 
significantly associated with high frequency of metastatic 
disease. In support of this, we also observed elevated LOX 
expression in the nucleus of the metastatic colon cancer 
cell line (SW620), a cell line derived from a lymph node 
metastases taken from the same patient as the isogenically 
matched non-metastatic colon cancer cell line (SW480). 
In addition to this, our previous work has shown that 
overexpression of LOX in the non-metastatic SW480 
cell line leads to increased tumour cell proliferation and 
Table 2: LOX expression in the primary rectal cancer in relation to biological variables
LOX expression
Variables Cytoplasmic Nuclear
Low (%) High (%) P-value Low (%) High (%) P-value
NF-κB 0.388 < 0.001
 Low 15 (17) 74 (83) 84 (94)  5 (6)
 High 11 (23) 37 (77) 34 (71) 14 (29)
Ki-67 0.258 0.050
 Low  7 (13) 45 (87) 49 (94)  3 (6)
 High 12 (22) 43 (78) 45 (82) 10 (18)
Survivin 0.029 0.215
 Low 14 (22) 50 (78) 57 (89)  7 (11)
 High  0 (0) 18 (100) 14 (78)  4 (22)
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metastasis both in vitro and in vivo. In contrast, knocking 
down of LOX expression in the SW620 metastatic cell 
line significantly reduces tumour cell proliferation and 
metastasis [15, 20]. Moreover, our latest results show that 
a high expression of LOX in primary tumour cells leads 
to tumour-driven pre-metastatic bone lesions whereas 
inhibition of LOX abrogates this process [19]. Taken all 
of these results together, it has been highly implied that 
nuclear localisation of LOX plays an important role in the 
process of cancer metastasis.
Our data further show that high nuclear expression 
of LOX was positively correlated with poor survival in 
rectal cancer patients in multivariable analysis. Recently, 
LOX has been clinically validated as a prognostic 
biomarker for metastatic head and neck cancer [10]. 
This work complements our findings and, furthermore, 
LOX has also been proposed to offer similar prognostic 
value in oral and oropharyngeal squamous carcinoma, 
whereby high expression is correlated with poor disease-
free and overall survival [11]. Importantly though, despite 
implicating overall LOX expression, neither of these 
papers profiled the specific cellular localisation of LOX in 
tumour tissues, making this the first report to do so.
 In the present study, our data showed that nuclear 
rather than cytoplasmic LOX protein expression in 
the primary rectal cancer was positively correlated 
with phospho-NF-κB p65 expression. It was originally 
shown that the LOX-PP could inhibit NF-κB activity 
and induced phenotypic reversion of cancer cells 
[17, 29]. However, a recent paper has reported that LOX 
expression displayed a positive correlation with NF-κB 
p65 expression in granulosa cells of ovarian tissue [30]. 
Notably, the antibody used in their study recognized 
both the LOX proenzyme and mature enzyme, yet they 
further demonstrated that NF-κB could up-regulate LOX 
gene expression by binding to its promoter. However, the 
authors did not assess the localisation of LOX protein. 
Since nuclear LOX presence may be involved in affecting 
specific gene expression patterns, we speculate that 
there may exist a positive LOX-NF-κB feedback loop 
promoting cancer metastasis in CRC. LOX enzyme may 
activate NF-κB in the nucleus, and activated NF-κB thus 
in turn further increase LOX expression. Nevertheless, 
it is too early to speculate on the detailed mechanisms 
underlying the relationship between LOX and NF-κB, and 
as such requires further investigation. 
We also analysed whether RT affected the LOX 
expression and localisation in patient samples and cell 
lines since preoperative RT is the standard treatment 
for rectal cancer patients. Our results show that LOX 
expression both in the cytoplasm and in the nucleus 
increased in normal mucosa samples after RT. This is in 
line with other work which has shown increases in LOX 
expression in radiation lung injury [31]. Our previous 
work has also shown that the activity of increased LOX 
expression induced in lung tissue by radiation, will 
enhance metastatic colonisation of cells [32]. Although 
it has been demonstrated that radiation can induce LOX 
secretion in several types of tumour cells [33], our data 
did not show any evidence of significant differences in 
either cytoplasmic or nuclear LOX expression related to 
RT in either patient samples or in vitro cancer cells. This 
suggests that CRC tumour cells, which already exhibit 
elevated LOX expression, do not upregulate LOX further 
in response to RT. This allows us to use primary tumour 
LOX expression and localisation as a robust prognostic 
indicator for patients at high risk of relapse independent 
of whether they received preoperative RT.
In conclusion, this study demonstrated that LOX 
expression in the nucleus is a promising prognostic 
biomarker in rectal cancer patients. It sheds a new light on 
better understanding the complex and crucial role of LOX 
in cancer beyond its well-known extracellular matrix-
modifying function. 
MATERIALS AND METHODS
Patient material
The patients were from the South-East Swedish 
Health Care region and participated in the randomized 
Swedish rectal cancer trial of preoperative RT between 
1987 and 1990 [21] Each participant signed the informed 
consent. The patient cohort included 137 primary rectal 
adenocarcinomas, 116 normal mucosa specimens (104 
corresponding to the primary tumour, i.e., normal mucosa 
and primary tumour from the same patient) that were 
histologically free from cancer and taken from the margin 
of distant surgical resection, and 47 lymph node metastases 
(42 corresponding to the primary tumour, also in the 
radiation field). Of the 137 patients (average age, 66.4 
years), 77 underwent surgery alone and 60 received RT 
followed by tumour resection. RT was given with 25 Gy 
in 5 fractions within a median of 7 days (range, 4–12 
days). Surgery was then carried out in a median of 3 days 
(range, 0–11 days) after RT. None of the patients received 
preoperative or adjuvant chemotherapy. The mean follow-
up period was 100 months (range, 0–309 months), and 
information on local and distant recurrence, DFS and 
OS were obtained from patient medical records. The 
characteristics of the patients and tumours are presented 
in Supplementary Table 2.
Human colon cancer cell lines
The SW480 and SW620 colon cancer cell lines 
were obtained from the American Type Culture Collection 
(Manassas, VA). SW480 cell line was established from 
primary adenocarcinoma of the colon, and the SW620 
from metastatic lymph node, taken from the same patient 
one year later. The cells were kept at 37°C and 5% 
CO2 in Eagle’s MEM (Sigma-Aldrich, St Louis, MO) 
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supplemented with 10% heat-inactivated fetal bovine 
serum albumin (GIBCO, Invitrogen, Paisley, UK) and 
1% Penicillin-streptomycin (GIBCO). The HCT116 
colon cancer cell line was obtained from the core cell 
center (Johns Hopkins University, Baltimore, MD), and 
was maintained in McCoy’s 5A medium (Sigma-Aldrich) 
supplemented with 10% heat-inactivated fetal bovine 
serum albumin (GIBCO) and 1% Penicillin-streptomycin 
(GIBCO) and kept in the same manner as SW480 and 
SW620. All cell lines were routinely tested as negative 
for mycoplasma.
Radiation of cancer cell lines
All experiments were carried out in biological 
triplicate. Briefly, 1 × 106 SW480 or SW620 cells were 
plated into standard 85 mm tissue culture plates 24 hours 
prior to radiation treatment. Cells were irradiated using the 
Faxitron CP160 X-Ray irradiator with either 2Gy or 5Gy 
at a rate of 0.7Gy per minute. Control cells were mock-
irradiated under the same conditions. 
IHC
IHC staining for LOX expression was done on 4 µm 
tissue microarray sections from paraffin-embedded surgical 
specimens. Sections were deparaffinized by immersing 
the slides twice in 100% xylene at room temperature for 
10 minutes each. This was followed by incubating twice 
in 100% ethanol for 10 minutes each, and rehydrating 
with decreasing concentrations of ethanol (90% and 70%; 
vol/vol in water, 10 minutes each) before a final 5-minute 
incubation in water. Antigen retrieval was carried out in 
a target retrieval citrate buffer (pH 6.0) (Dako, Glostrup, 
Denmark) at 95°C for 15 minutes. The sections were 
allowed to cool for 15 minutes and rinsed with phosphate-
buffered saline (PBS). The sections were incubated in 
3% H2O2-methanol for 5 minutes to block the activity of 
endogenous peroxidase. After being washed in PBS, the 
sections were incubated with protein block (Dako) for 
10 minutes to reduce nonspecific background staining. 
The sections were incubated with the anti-LOX polyclonal 
rabbit antibody (synthesized by OpenBiosystems which 
targets a conserved peptide sequence from the active site 
of human and mouse proteins and has been shown not to 
bind other LOX family members [35]) in a 1:50 dilution 
with antibody diluent buffer overnight. After being washed 
in PBS, the sections were incubated with a secondary 
antibody, Envision System Labelled Polymer-HRP Anti-
Rabbit (Dako) for 25 minutes. The sections were rinsed in 
PBS before reacting with Liquid DAB+ (Dako) to produce 
coloration. Finally, the sections were lightly counterstained 
with hematoxylin. 
The immunostaining was scored by two independent 
observers based on the intensity and localisation without 
information of the patients. The intensity in epithelial 
cells or tumour cells was scored as negative, weak (light 
yellow), moderate (yellow brown), and strong staining 
(brown). The staining patterns were graded as cytoplasmic 
or nuclear. In the case of discrepant scoring results, a 
consensus score was reached after re-evaluation. For 
statistical analyses, negative and weak-stained cases were 
considered as low-expressing group, and moderate and 
strong staining as high-expressing group. The expression 
of NF-κB, Ki-67 and survivin was determined by IHC 
at our laboratory on the same patient samples as in the 
present study. The used cutoff points were the same as in 
the corresponding publications [34, 35, 36].
Confocal microscopy    
Cells were seeded on coverslips and allowed 
to adhere overnight in 6-well plates, then fixed with 
4% paraformaldehyde, and permeabilized with 0.5% 
triton-x-100 in PBS. The cells were blocked in blocking 
buffer for 30 minutes, and then stained with the primary 
antibody (described above) in a 1:50 dilution and 
incubated at room temperature for 1.5 hours. The reaction 
was stopped by adding wash buffer and rinsing 3 times. 
Cells were then incubated with anti-rabbit Alexa Fluor 
488 conjugated secondary antibody (Thermo Fisher 
Scientific, Waltham, MA) for 30 minutes at 37°C. 
Coverslips with cells were fixed on glasses by adding 
mounting medium with Diamidino-2-phenylindole 
(DAPI) (Olink Bioscience, Uppsala, Sweden). Prepared 
cells were analysed in upright Zeiss Axio Imager with 
LSM 700 confocal microscope (Zeiss, Germany) using a 
63× oil immersion objective.
Western blot
Cytoplasmic and nuclear extracts were prepared as 
follows. After 24 hours post radiation, cells were scraped 
into 1 mL PBS, and fractionated using NP-40 buffer 
to generate total, cytoplasmic and nuclear fractions. 
Fractions were mixed with Laemmli buffer and sonicated 
before SDS-PAGE immunoblotting for LOX. The 
protein concentration was determined by the colorimetric 
Bradford protein assay reagent. Equal amounts of 
protein were loaded, separated by electrophoresis, 
and transferred to PVDF membrane. Membranes were 
blocked with 5% milk powder in TBS containing 
0.1% Tween-20 for 1 hour at room temperature and 
incubated with the primary antibody (described above) 
(1:200) overnight at 4°C. The membranes were washed 
and subsequently incubated with the secondary HRP-
conjugated polyclonal goat anti-rabbit (1:10000, DAKO) 
for 1 hour. Protein bands were detected using ECL 
plus Western Blotting Detection System (Amersham 
Bioscience/GE Healthcare, Piscataway, NJ). Anti-β-actin 
(1: 5000, Cell Signaling Technology, Danvers, MA) was 
used as a loading control.
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Statistical analyses 
All statistical analyses were carried out by using 
STATISTICA software package (version 7.0; STATSOFT 
Inc., Tulsa, OK). McNemar’s or Person χ2 test was used 
to examine the significance of the differences in LOX 
expression among normal mucosa, primary tumour, and 
lymph node metastases, as well as the association of 
LOX expression with clinicopathological or biological 
variables. The relationship of LOX expression with 
survival was tested by using Kaplan–Meier analysis 
(Log rank test) and Cox proportional hazards regression 
analysis (likelihood ratio test). All tests were two sided 
and P-values of < 0.05 were considered as significant.
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